Ayala Pharmaceuticals, Inc.

Ayala Pharmaceuticals, Inc. is a clinical-stage oncology company specializing in developing and commercializing small molecule therapeutics for rare and aggressive cancers. Their lead product candidate, AL101, is a potent, selective, injectable small molecule gamma secretase inhibitor (GSI) in Phase II clinical trial for recurrent/metastatic adenoid cystic carcinoma with Notch-activating mutations. Additionally, the company is developing AL102, an oral small molecule GSI in Phase II/III pivotal study for desmoid tumors, and has a collaboration with Novartis to develop AL102 for multiple myeloma treatment.

Products

• AL101 - small molecule gamma secretase inhibitor for adenoid cystic carcinoma

• AL102 - small molecule gamma secretase inhibitor for desmoid tumors and multiple myeloma